Azenta, Inc.
AZTAAzenta, Inc. (AZTA) is a global provider of life science and laboratory automation solutions. The company specializes in research and development services, sample management, and laboratory products, supporting the pharmaceutical, biotech, and healthcare industries. Azenta focuses on enabling scientific discovery through innovative technology and streamlined workflows.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 23, 2021 | $0.10 | 2021-12-02 | 2021-12-03 |
| September 24, 2021 | $0.10 | 2021-09-02 | 2021-09-03 |
| June 25, 2021 | $0.10 | 2021-06-03 | 2021-06-04 |
| March 26, 2021 | $0.10 | 2021-03-04 | 2021-03-05 |
| December 17, 2020 | $0.10 | 2020-12-03 | 2020-12-04 |
Dividends Summary
- Consistent Payer: Azenta, Inc. has rewarded shareholders with 42 dividend payments over the past 10 years.
- Total Returned Value: Investors who held AZTA shares during this period received a total of $3.96 per share in dividend income.
- Latest Payout: The most recent dividend of $0.10/share was paid 1668 days ago, on December 23, 2021.
- Yield & Schedule: AZTA currently pays dividends quarterly with an annual yield of 1.52%.
- Dividend Growth: Since 2011, the dividend payout has grown by 25.0%, from $0.08 to $0.10.
- Dividend Reliability: AZTA has maintained or increased its dividend for 42 consecutive payments.
Company News
Azenta, Inc. (AZTA) faces an ongoing securities fraud investigation following disappointing Q2 2026 earnings results on May 5, 2026. The company missed consensus estimates, reported a $149 million goodwill impairment, and significantly reduced its 2026 guidance, causing the stock to plummet 25.3% to $18.38 per share. A securities law firm is inve...
Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026, but disclosed a $149 million goodwill impairment tied to its Multiomics segment in May 2026, alongside a $160.8 million net loss and substantial guidance reduction. The company did not reference the impairment risk during its February r...
Law firm Bragar Eagel & Squire is investigating Azenta, Inc. following the company's May 5, 2026 announcement of disappointing Q2 fiscal 2026 results, execution gaps, and a $149 million goodwill impairment charge. Azenta significantly lowered its full-year guidance and extended its long-range plan targets, causing its stock to plummet 25% from $2...
Azenta, Inc. reported disappointing Q2 fiscal 2026 results with execution gaps and weak demand, recording a $149 million goodwill impairment charge. The company significantly reduced its full-year guidance and extended long-range plan targets, causing its stock to plunge 25% on May 6, 2026. Law firm Kirby McInerney LLP is investigating potential ...
The Schall Law Firm announced an investigation into Azenta, Inc. for potential securities law violations following the company's May 5, 2026 earnings announcement. Azenta missed analyst estimates on revenue and EPS due to execution shortfalls and weak demand, leading to a 25.3% stock price decline and a reduced full-year 2026 outlook.
